Yahoo
NasdaqCM - Delayed Quote USD

Cellyan Biotechnology Co., Ltd (HKPD)

1.9800 -0.2100 (-9.59%)
At close: October 30 at 4:00:00 PM EDT
Chart Range Bar
Loading chart for HKPD
  • Previous Close 2.1900
  • Open 2.1101
  • Bid 0.1034 x 100
  • Ask 0.0949 x 100
  • Day's Range 1.8400 - 2.1240
  • 52 Week Range 1.6200 - 29.0000
  • Volume 26,997
  • Avg. Volume 179,824
  • Market Cap (intraday) 4.882M
  • Beta (5Y Monthly) --
  • PE Ratio (TTM) --
  • EPS (TTM) -1.3800
  • Earnings Date --
  • Forward Dividend & Yield -- (0.00%)
  • Ex-Dividend Date --
  • 1y Target Est --

Cellyan Biotechnology Co., Ltd, an investment holding company, engages in the over-the counter (OTC) pharmaceutical business in Hong Kong and Mainland China. The company provides OTC pharmaceutical cross-border procurement and distribution and e-commerce supply chain services. It also offers customs clearance, drugs enlisting, warehouse, and other logistics services. In addition, it provides value-added services such as labeling, extended storage, product inspection, batch processing, and logistics support, as well as sales of health supplements and non-pharmaceutical products. The company serves e-commerce platform logistics partners, merchants, and Chinese e-commerce platforms as well as pharmaceutical distributors. The company was formerly known as Hong Kong Pharma Digital Technology Holdings Limited and changed its name to Cellyan Biotechnology Co., Ltd in December 2025. Cellyan Biotechnology Co., Ltd was incorporated in 2023 and is based in Yau Tong, Hong Kong.

www.9zt.hk

11

Full Time Employees

March 31

Fiscal Year Ends

Healthcare

Sector

Recent News

View More

Performance Overview

Trailing total returns as of 10/30/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .

YTD Return

HKPD
87.99%
S&P 500 (^GSPC)
10.73%

1-Year Return

HKPD
92.14%
S&P 500 (^GSPC)
11.11%

3-Year Return

HKPD
97.17%
S&P 500 (^GSPC)
81.91%

5-Year Return

HKPD
97.17%
S&P 500 (^GSPC)
64.59%

Statistics

View More

Valuation Measures

Annual
  • Market Cap

  • Enterprise Value

  • Trailing P/E

  • Forward P/E

  • PEG Ratio (current)

  • Price/Sales (ttm)

  • Price/Book (mrq)

  • Enterprise Value/Revenue

  • Enterprise Value/EBITDA

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    -8.46%

  • Return on Assets (ttm)

    -5.64%

  • Return on Equity (ttm)

    -15.59%

  • Revenue (ttm)

    13.43M

  • Net Income Avi to Common (ttm)

    -1.14M

  • Diluted EPS (ttm)

    -1.3800

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    221.84k

  • Total Debt/Equity (mrq)

    13.13%

  • Levered Free Cash Flow (ttm)

    -6.51M

Company Insights

Research Reports

View More

People Also Watch

Mobilize your Website
View Site in Mobile | Classic
Share by: